NASDAQ:AUGX Augmedix (AUGX) Stock Price, News & Analysis → My top 100 stocks… (From DTI) (Ad) Free AUGX Stock Alerts $2.85 +0.06 (+2.15%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.75▼$2.8750-Day Range$2.79▼$4.6852-Week Range$2.61▼$6.25Volume320,582 shsAverage Volume365,688 shsMarket Capitalization$138.91 millionP/E RatioN/ADividend YieldN/APrice Target$5.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Augmedix alerts: Email Address Augmedix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside81.3% Upside$5.17 Price TargetShort InterestHealthy2.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.83Based on 2 Articles This WeekInsider TradingSelling Shares$1.01 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector590th out of 913 stocksBusiness Services, Not Elsewhere Classified Industry69th out of 89 stocks 3.5 Analyst's Opinion Consensus RatingAugmedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAugmedix has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.83% of the float of Augmedix has been sold short.Short Interest Ratio / Days to CoverAugmedix has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Augmedix has recently increased by 49.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAugmedix does not currently pay a dividend.Dividend GrowthAugmedix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUGX. Previous Next 0.7 News and Social Media Coverage News SentimentAugmedix has a news sentiment score of -0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Augmedix this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Augmedix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Augmedix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,005,527.00 in company stock.Percentage Held by Insiders10.97% of the stock of Augmedix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.11% of the stock of Augmedix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Augmedix is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Augmedix is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAugmedix has a P/B Ratio of 5.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Augmedix Stock (NASDAQ:AUGX)Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.Read More AUGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUGX Stock News HeadlinesApril 12, 2024 | insidertrades.comAugmedix, Inc. (NASDAQ:AUGX) Insider Sells $97,377.54 in StockApril 10, 2024 | insidertrades.comIan Shakil Sells 37,780 Shares of Augmedix, Inc. (NASDAQ:AUGX) StockApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 10, 2024 | insidertrades.comAugmedix, Inc. (NASDAQ:AUGX) Insider Sells $207,089.61 in StockApril 5, 2024 | insidertrades.comAugmedix, Inc. (NASDAQ:AUGX) Insider Ian Shakil Sells 45,906 SharesApril 4, 2024 | insidertrades.comAugmedix, Inc. (NASDAQ:AUGX) Insider Sells $230,603.98 in StockApril 2, 2024 | insidertrades.comAugmedix, Inc. (NASDAQ:AUGX) Insider Ian Shakil Sells 31,994 SharesApril 24, 2024 | finance.yahoo.comAugmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency DepartmentsApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 24, 2024 | globenewswire.comAugmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency DepartmentsApril 19, 2024 | investorplace.com3 Penny Stocks That Could Make a Big Comeback by the End of Q2April 17, 2024 | msn.comAugmedix (AUGX) Price Target Decreased by 6.38% to 6.19April 14, 2024 | investing.comAugmedix's chief strategy officer sells shares worth over $369kApril 12, 2024 | finance.yahoo.comInsider Sell: Augmedix Inc's (AUGX) Chief Strategy Officer Ian Shakil Sells 92,787 SharesApril 11, 2024 | investing.comAugmedix shares upgraded to Outperform by Evercore ISIApril 9, 2024 | markets.businessinsider.comAnalyst Ratings For AugmedixApril 9, 2024 | globenewswire.comAugmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual CareApril 5, 2024 | finance.yahoo.comAugmedix Inc (AUGX) Chief Strategy Officer Ian Shakil Sells 109,961 SharesApril 4, 2024 | globenewswire.comAugmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems NationwideMarch 24, 2024 | seekingalpha.comAugmedix: Secular AI Tailwinds, But Still Unattractive Risk-RewardMarch 23, 2024 | finance.yahoo.comAugmedix Full Year 2023 Earnings: In Line With ExpectationsMarch 21, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their Augmedix, Inc. (NASDAQ:AUGX) Price Target To US$6.13March 20, 2024 | finance.yahoo.comAugmedix, Inc. (NASDAQ:AUGX) Q4 2023 Earnings Call TranscriptMarch 18, 2024 | benzinga.comRecap: Augmedix Q4 EarningsMarch 18, 2024 | globenewswire.comAugmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023March 12, 2024 | globenewswire.comAugmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix GoMarch 8, 2024 | globenewswire.comAugmedix to Announce Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024See More Headlines Receive AUGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/26/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:AUGX CUSIPN/A CIK1769804 Webwww.augmedix.com Phone888-669-4885FaxN/AEmployees1,430Year FoundedN/APrice Target and Rating Average Stock Price Target$5.17 High Stock Price Target$5.50 Low Stock Price Target$5.00 Potential Upside/Downside+81.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,170,000.00 Net Margins-42.74% Pretax Margin-42.42% Return on Equity-308.50% Return on Assets-41.57% Debt Debt-to-Equity Ratio0.66 Current Ratio2.41 Quick Ratio2.41 Sales & Book Value Annual Sales$44.85 million Price / Sales3.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book5.09Miscellaneous Outstanding Shares48,740,000Free Float43,393,000Market Cap$138.91 million OptionableOptionable Beta-0.16 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Emmanuel Krakaris (Age 65)President, CEO, Secretary & Director Comp: $734.33kMr. Ian Shakil (Age 39)Founder, Chief Strategy Officer & Director Ms. Sandra Breber (Age 66)Chief Operating Officer Comp: $446.05kMr. Saurav Chatterjee Ph.D. (Age 52)Chief Technology Officer Comp: $438.05kMr. Paul Louis Ginocchio (Age 54)Chief Financial Officer Todd HolvickHead of Legal & ComplianceLia WallickHead of PeopleDr. Davin Lundquist M.D.Chief Medical OfficerMr. Jonathan Hawkins (Age 54)Chief Revenue Officer Comp: $417.71kMr. Tomer LevySenior Vice President of EngineeringMore ExecutivesKey CompetitorsAmerican WellNYSE:AMWLMultiPlanNYSE:MPLNDelcath SystemsNASDAQ:DCTHSyros PharmaceuticalsNASDAQ:SYRSAnnovis BioNYSE:ANVSView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 60,500 shares on 4/25/2024Ownership: 0.000%Norden Group LLCBought 6,401 shares on 4/19/2024Ownership: 0.039%Ian ShakilSold 500 sharesTotal: $1,900.00 ($3.80/share)Ian ShakilSold 24,778 sharesTotal: $97,377.54 ($3.93/share)Ian ShakilSold 37,780 sharesTotal: $149,986.60 ($3.97/share)View All Insider TransactionsView All Institutional Transactions AUGX Stock Analysis - Frequently Asked Questions Should I buy or sell Augmedix stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Augmedix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AUGX shares. View AUGX analyst ratings or view top-rated stocks. What is Augmedix's stock price target for 2024? 3 analysts have issued 12-month price targets for Augmedix's shares. Their AUGX share price targets range from $5.00 to $5.50. On average, they expect the company's share price to reach $5.17 in the next year. This suggests a possible upside of 81.3% from the stock's current price. View analysts price targets for AUGX or view top-rated stocks among Wall Street analysts. How have AUGX shares performed in 2024? Augmedix's stock was trading at $5.85 at the start of the year. Since then, AUGX shares have decreased by 51.3% and is now trading at $2.85. View the best growth stocks for 2024 here. Are investors shorting Augmedix? Augmedix saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 831,500 shares, an increase of 11.2% from the March 15th total of 748,000 shares. Based on an average trading volume of 377,800 shares, the days-to-cover ratio is currently 2.2 days. Approximately 1.9% of the shares of the company are sold short. View Augmedix's Short Interest. When is Augmedix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our AUGX earnings forecast. How were Augmedix's earnings last quarter? Augmedix, Inc. (NASDAQ:AUGX) issued its quarterly earnings results on Monday, March, 18th. The company reported ($0.09) EPS for the quarter. The firm had revenue of $12.68 million for the quarter, compared to the consensus estimate of $12.30 million. Augmedix had a negative trailing twelve-month return on equity of 308.50% and a negative net margin of 42.74%. What guidance has Augmedix issued on next quarter's earnings? Augmedix issued an update on its FY 2024 earnings guidance on Monday, March, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $60.0 million-$62.0 million, compared to the consensus revenue estimate of $61.5 million. When did Augmedix IPO? Augmedix (AUGX) raised $40 million in an initial public offering (IPO) on Tuesday, October 26th 2021. The company issued 10,000,000 shares at a price of $4.00 per share. William Blair, B. Riley Securities, Benchmark and Lake Street acted as the underwriters for the IPO. Who are Augmedix's major shareholders? Augmedix's stock is owned by a variety of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%) and Norden Group LLC (0.04%). Insiders that own company stock include Ian Shakil and Paul Ginocchio. View institutional ownership trends. How do I buy shares of Augmedix? Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AUGX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Augmedix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
